Skip to main content
Premium Trial:

Request an Annual Quote

Susceptibility Tests Will Generate One-Third of Genomic-Diagnostics Revenue

NEW YORK, Aug. 14 - Testing for disease susceptibility will account for one-third of the total genomic-diagnostic revenues this year, according to a report released today.


The report, by health-care research firm Decision Resources, shows that revenues from sales of assays for disease-susceptibility testing, prognostics, and monitoring are projected to reach $115 million in 2002 from an estimated $71 million collected last year. If fulfilled, this forecast means that these applications will account for about 90 percent of the total genomic-diagnostics market.


Companies that currently occupy the genomics-diagnostics space include Affymetrix, Cepheid, DNA Sciences, Myriad Genetics, Nanogen, and Third Wave Technologies.


Still, "there aren't many [of these] products on the market right now," Karen O'Connor, an analyst with Decision Resources, told GenomeWeb. "These estimates have ... been based on products that have not come out to market yet."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.